BIVI On Other Exchanges
Symbol
Exchange
OTC US

biovie inc (BIVI) Snapshot

Open
--
Previous Close
--
Day High
--
Day Low
--
52 Week High
-- - --
52 Week Low
-- - --
Market Cap
--
Average Volume 10 Days
--
EPS TTM
--
Shares Outstanding
--
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for BIOVIE INC (BIVI)
\

Related News

No related news articles were found.

biovie inc (BIVI) Related Businessweek News

No Related Businessweek News Found

biovie inc (BIVI) Details

BioVie Inc., a clinical stage biotechnology company, engages in the discovery, development, and commercialization of drugs therapies in the United States. It develops BIV201, which is in Phase IIa clinical trial for the treatment of ascites due to chronic liver cirrhosis. The company was formerly known as NanoAntibiotics, Inc. and changed its name to BioVie Inc. in July 2016. BioVie Inc. was founded in 2013 and is based in Los Angeles, California.

1 Employees
Last Reported Date: 10/5/18
Founded in 2013

biovie inc (BIVI) Top Compensated Officers

President, COO & Director
Total Annual Compensation: $250.0K
Compensation as of Fiscal Year 2018.
biovie inc
Biovie Inc. Reports Earnings Results for the Third Quarter Ended March 31, 2019

BioVie Inc. announced earnings results for the third quarter ended March 31, 2019. For the third quarter, the company announced operating loss was USD 848,289 compared to USD 691,215 a year ago. Net loss was USD 848,041 compared to USD 692,557 a year ago. Basic earnings per share from continuing operations was USD 0 compared to basic loss per share from continuing operations of USD 0.01 a year ago. For the nine months, operating loss was USD 1.840 million compared to USD 1.848 million a year ago. Net loss was USD 1.788 million compared to USD 1.858 million a year ago. Basic loss per share from continuing operations was USD 0.01 compared to USD 0.02 a year ago.

BioVie Achieves Primary Objectives in Phase 2a Clinical Trial of BIV201 in Refractory Ascites

BioVie Inc. announced top-line results for its Phase 2a clinical trial of BIV201 (continuous infusion terlipressin) in six patients with refractory ascites due to advanced liver cirrhosis. The primary objectives of this initial open-label study were to assess the safety, tolerability, and steady state pharmacokinetics (PK) of terlipressin administered as a continuous infusion for 28 days to cirrhotic patients with refractory ascites. Exploratory objectives were to assess the reduction in requirement of frequency and volume of paracentesis with continuous infusion of terlipressin. The following results were observed: Continuous infusion of terlipressin via portable infusion pump was maintained for 28 days in three patients with refractory ascites, and all patients remained hemodynamically stable during treatment. The steady state plasma concentration data characterized terlipressin pharmacokinetics (PK) within the predicted PK model concentrations. Four of the six patients treated with BIV201 experienced an increase in the number of days between paracenteses ranging from 71% to 414% compared to prior to initiating therapy. BioVie is planning to share detailed study results with the FDA in a meeting scheduled for the first half of 2019. At that time, the Company expects to receive guidance for planning the next steps in the BIV201 clinical development plan.

BioVie Inc. Presents at ThinkEquity Conference, May-02-2019 02:00 PM

BioVie Inc. Presents at ThinkEquity Conference, May-02-2019 02:00 PM. Venue: The Mandarin Oriental Hotel, 80 Columbus Circle (at 60th St), New York, New York, United States. Speakers: Terren S. Peizer, Chairman & CEO.

 

The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

BIVI Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for BIVI.
View Industry Companies
 

Industry Analysis

BIVI

Industry Average

Valuation BIVI Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book 11.1x
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact BIOVIE INC, please visit www.biovieinc.com. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.